Effect Of Addition Of Cisplatin And Capecitabine To AG Regimen In PDAC

Synopsis Clinical trial evidence suggested that the addition of Cisplatin and Capecitabine To AG Regimen (i.e. first-line nab-paclitaxel and gemcitabine) resulted in disease control without affecting tolerability in Pancreatic Ductal Adenocarcinoma (PDAC) or Pancreatic Adenocarcinoma. This week’s “MED FACT” discusses a clinical study from European Journal of Cancer, “ A randomized phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma” . September 2018.

Authors : Reni M, Zanon S, Balzano G et al. Key Takeaways: Addition of Cisplatin and Capecitabine To AG Regimen resulted in promising disease control without affecting tolerability in resectable PDAC. Objective: To investigate the effect AG regimen with or without capecitabine and cisplatin in locally advanced or borderline…